Farrow, Buckminster <br/><br/>
Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.  [electronic resource] 

 -  Surgery  Aug 2003 
 - 206-12 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0039-6060 
<br/><br/><label>Standard No.: </label>10.1067/msy.2003.221  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Chromans--pharmacology<br/>Humans<br/>Integrins--antagonists & inhibitors<br/>Matrix Metalloproteinase Inhibitors<br/>Neoplasm Invasiveness--prevention & control<br/>Pancreatic Neoplasms--metabolism<br/>Prostaglandin D2--analogs & derivatives<br/>Receptors, Cytoplasmic and Nuclear--metabolism<br/>Rosiglitazone<br/>Thiazoles--pharmacology<br/>Thiazolidinediones<br/>Tissue Plasminogen Activator--antagonists & inhibitors<br/>Transcription Factors--metabolism<br/>Troglitazone<br/>Tumor Cells, Cultured